The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dabrafenib and trametinib in the treatment of BRAF-mutated anaplastic thyroid cancers (ATC).
 
Irini Yacoub
No Relationships to Disclose
 
Nancy Lee
Consulting or Advisory Role - Elsie Pharmaceuticals; Galera Therapeutics; GlaxoSmithKline; LEO SAB; Merck; Merck Serono; Mirati Therapeutics; Nanobiotix; Regeneron
Speakers' Bureau - Shanghai Joanne Medical LTD; Varian Medical Systems; Yingming Consulting
 
Nadeem Riaz
Honoraria - Oxford university press; PeerView
Consulting or Advisory Role - Mirati Therapeutics; Repare Therapeutics
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Paige.AI; Pfizer; Repare Therapeutics
Travel, Accommodations, Expenses - Varian Medical Systems
 
Sean McBride
Consulting or Advisory Role - Janssen
Research Funding - Genentech
 
Loren Michel
No Relationships to Disclose
 
Anuja Kriplani
No Relationships to Disclose
 
Ian Ganly
No Relationships to Disclose
 
Jennifer Cracchiolo
Honoraria - Medscape
 
Richard Wong
No Relationships to Disclose
 
Alan Ho
Consulting or Advisory Role - AffyImmune Therapeutics; Coherus Biosciences; Eisai; Exelixis; Hookipa Biotech; InhibRx; Kura Oncology; Lepu Biopharma; Nested Therapeutics; Rgenta; Takeda
Speakers' Bureau - Mt. Sinai; Physicans' Education Resource
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Daiichi; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Hookipa Biotech; Kura Oncology; Merck; Novartis; OncC4; Poseida; Remix Therapeutics; Rgenta; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Eric Sherman
Consulting or Advisory Role - AffyImmune Therapeutics; Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - Fore Biotherapeutics (Inst); HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst)